VALNEVA (EPA:VLA) | WebDisclosure

Basculer en Français

11060	Companies
242617	Keywords
170868	Articles
130587	Press releases

Home
Companies
VALNEVA

PRESS RELEASE

published on 08/19/2025 at 10:39, 1 year 1 month ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH has published a research update on Valneva SE, maintaining their BUY rating and EUR 8.10 price target, following better-than-expected Q2/25 results and positive outlook on vaccines

BUY Rating Research Update Q2 Results Valneva SE Vaccine Outlook
BRIEF

published on 08/18/2025 at 07:05, 1 year 1 month ago

Le Vaccin IXCHIQ® de Valneva Autorisé au Canada pour les 12 Ans et Plus

Valneva Santé Canada Autorisation Vaccin Chikungunya
BRIEF

published on 08/18/2025 at 07:05, 1 year 1 month ago

Valneva's IXCHIQ® Vaccine Authorized in Canada for Ages 12 and Older

Health Canada Valneva Vaccine Authorisation Chikungunya
PRESS RELEASE

published on 08/18/2025 at 07:00, 1 year 1 month ago

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
Valneva's Chikungunya Vaccine IXCHIQ® authorized in Canada for individuals aged 12 and older. Health Canada grants marketing authorization for disease prevention

Canada Health Valneva Vaccine Chikungunya
PRESS RELEASE

published on 08/18/2025 at 07:00, 1 year 1 month ago

Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé au Canada pour les personnes âgées de 12 ans et plus
Valneva obtient l'autorisation de Santé Canada pour son vaccin IXCHIQ® contre le chikungunya chez les + de 12 ans. Le vaccin est approuvé en Europe pour les adolescents. Les données de phase 3 montrent une réponse immunitaire durable

Valneva Autorisation Vaccin Chikungunya IXCHIQ®
BRIEF

published on 08/12/2025 at 07:05, 1 year 1 month ago

Rapport financier semestriel 2025 de Valneva : croissance et évolutions stratégiques

Résultats Financiers Partenariats Stratégiques Croissance Des Revenus Gestion De Trésorerie Mises À Jour Réglementaires
BRIEF

published on 08/12/2025 at 07:05, 1 year 1 month ago

Valneva's Half-Year 2025 Financial Report: Growth and Strategic Moves

Financial Results Strategic Partnerships Revenue Growth Cash Management Regulatory Updates
PRESS RELEASE

published on 08/12/2025 at 07:00, 1 year 1 month ago

VALNEVA : Rapport Semestriel 2025
PRESS RELEASE

published on 08/12/2025 at 07:00, 1 year 1 month ago

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
Valneva SE reports €97.6 million revenues in H1 2025, confirms 2025 financial outlook. Highlights financial results, R&D progress, and commercial updates

Revenues Financial Results Valneva SE R&D Progress 2025 Outlook Commercial Updates
PRESS RELEASE

published on 08/12/2025 at 07:00, 1 year 1 month ago

Valneva publie ses résultats financiers du premier semestre 2025 et fait un point sur ses activités
Valneva publie ses résultats financiers du premier semestre 2025 et fait un point sur ses activités. Chiffre d’affaires en hausse, trésorerie solide et perspectives confirmées. Détails disponibles sur le site de la société

Résultats Financiers Perspectives Valneva Vaccins Premier Semestre 2025

Accesswire

Published on 09/23/2026 at 15:42, 54 minutes ago

Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 2 hours 5 minutes ago

First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 2 hours 6 minutes ago

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Published on 09/23/2026 at 14:00, 2 hours 36 minutes ago

Integrated Rewards Launches "Celebrate Canadian" Campaign to Connect Canadian Brands with Millions of Consumers
Published on 09/23/2026 at 13:30, 3 hours 6 minutes ago

Engineering Cost Study Validates Commercial-Scale U.S. HPMSM Capital Cost and Establishes EMM Capital Cost for Electric Metals' North Star Manganese Project

View all ACCESSWIRE

EQS Group

Published on 09/23/2026 at 15:42, 54 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 09/23/2026 at 15:41, 54 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Permanent TSB Group Holdings plc
Published on 09/23/2026 at 15:41, 55 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 09/23/2026 at 15:40, 56 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 09/23/2026 at 15:40, 56 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Rotork plc

Les Echos

Published on 09/23/2026 at 08:00, 8 hours 36 minutes ago

Résultats semestriels 2026 - ANR par action : 101,90 €, en progression de 8,18 % - Capitaux propres consolidés : 774,5 M€
Published on 09/22/2026 at 18:10, 22 hours 26 minutes ago

Financial statements - 30 june 2026
Published on 09/22/2026 at 18:00, 22 hours 36 minutes ago

Consolidated results for the first half of 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 18:00, 22 hours 36 minutes ago

Résultats consolidés du premier semestre 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 17:45, 22 hours 51 minutes ago

Imerys-09-2026-information-share-capital-and-voting-rights-as-of-31-August-2026

View all LES ECHOS COMFI WIRE